Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lutz van Heek

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Diagnostics (Basel, Switzerland)|February 25, 2022
Influences on PET Quantification and InterpretationJulian M M Rogasch, Frank Hofheinz, Lutz van Heek, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 21, 2023
Patterns of PET-positive residual tissue at interim restaging and risk of treatment failure in advanced-stage Hodgkin's lymphoma: an analysis of the randomized phase III HD18 trial by the German Hodgkin Study GroupJustin Ferdinandus, Lutz van Heek, Katrin Roth, et al.
Nuklearmedizin. Nuclear Medicine|March 24, 2021
Avoidance of iodine deficiency/excess during pregnancy in Hashimoto's thyroiditisLutz van Heek, Christiane Staudacher, Michael Faust, et al.
Academic Radiology|December 28, 2023
PET/CT Reconstruction and Its Impact on [Measures of] Metabolic Tumor VolumeHenry Knaup, Jasmin Weindler, Lutz van Heek, et al.
EJNMMI Physics|December 13, 2018
Impact of different approaches to calculation of treatment activities on achieved doses in radioiodine therapy of benign thyroid diseasesJochen Hammes, Lutz van Heek, Melanie Hohberg, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 15, 2022
Dual-Tracer PET/CT Protocol with [<sup>18</sup>F]-FDG and [<sup>68</sup>Ga]Ga-FAPI-46 for Cancer Imaging: A Proof of ConceptKatrin S Roth, Conrad-Amadeus Voltin, Lutz van Heek, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|August 16, 2023
Dual-tracer PET/CT protocol with [<sup>18</sup>F]FDG and [<sup>68</sup>Ga]Ga-FAPI-46 outperforms single-tracer PET/CT with [<sup>18</sup>F]FDG in different cancer types, resulting in larger functional and gross tumor volumeSimone Wegen, Jasmin Weindler, Conrad-Amadeus Voltin, et al.
BMC Cancer|June 18, 2022
Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma - Data from the prospective, multicenter phase III HD16 trialLutz van Heek, Colin Stuka, Helen Kaul, et al.
European Journal of Haematology|August 30, 2023
Prognostic value of baseline metabolic tumor volume (MTV) for forecasting chemotherapy outcome in early-stage unfavorable Hodgkin lymphoma: Data from the phase III HD17 trialLutz van Heek, Jasmin Weindler, Claudia Gorniak, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|February 13, 2021
Pentixafor PET/CT for imaging of chemokine receptor 4 expression in esophageal cancer - a first clinical approachPhilipp Linde, Christian Baues, Simone Wegen, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Diagnostics (Basel, Switzerland)|February 25, 2022
Influences on PET Quantification and InterpretationJulian M M Rogasch, Frank Hofheinz, Lutz van Heek, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 21, 2023
Patterns of PET-positive residual tissue at interim restaging and risk of treatment failure in advanced-stage Hodgkin's lymphoma: an analysis of the randomized phase III HD18 trial by the German Hodgkin Study GroupJustin Ferdinandus, Lutz van Heek, Katrin Roth, et al.
Nuklearmedizin. Nuclear Medicine|March 24, 2021
Avoidance of iodine deficiency/excess during pregnancy in Hashimoto's thyroiditisLutz van Heek, Christiane Staudacher, Michael Faust, et al.
Academic Radiology|December 28, 2023
PET/CT Reconstruction and Its Impact on [Measures of] Metabolic Tumor VolumeHenry Knaup, Jasmin Weindler, Lutz van Heek, et al.
EJNMMI Physics|December 13, 2018
Impact of different approaches to calculation of treatment activities on achieved doses in radioiodine therapy of benign thyroid diseasesJochen Hammes, Lutz van Heek, Melanie Hohberg, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 15, 2022
Dual-Tracer PET/CT Protocol with [<sup>18</sup>F]-FDG and [<sup>68</sup>Ga]Ga-FAPI-46 for Cancer Imaging: A Proof of ConceptKatrin S Roth, Conrad-Amadeus Voltin, Lutz van Heek, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|August 16, 2023
Dual-tracer PET/CT protocol with [<sup>18</sup>F]FDG and [<sup>68</sup>Ga]Ga-FAPI-46 outperforms single-tracer PET/CT with [<sup>18</sup>F]FDG in different cancer types, resulting in larger functional and gross tumor volumeSimone Wegen, Jasmin Weindler, Conrad-Amadeus Voltin, et al.
BMC Cancer|June 18, 2022
Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma - Data from the prospective, multicenter phase III HD16 trialLutz van Heek, Colin Stuka, Helen Kaul, et al.
European Journal of Haematology|August 30, 2023
Prognostic value of baseline metabolic tumor volume (MTV) for forecasting chemotherapy outcome in early-stage unfavorable Hodgkin lymphoma: Data from the phase III HD17 trialLutz van Heek, Jasmin Weindler, Claudia Gorniak, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|February 13, 2021
Pentixafor PET/CT for imaging of chemokine receptor 4 expression in esophageal cancer - a first clinical approachPhilipp Linde, Christian Baues, Simone Wegen, et al.
Pageof 2